Persistence of Bactericidal Antibodies in Adolescents and Adults Aged 15 to 23 Years Who Received a Single Dose of Menactra or Menomune-A/C/Y/W-135 Five Years Earlier

Trial Profile

Persistence of Bactericidal Antibodies in Adolescents and Adults Aged 15 to 23 Years Who Received a Single Dose of Menactra or Menomune-A/C/Y/W-135 Five Years Earlier

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2014

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
  • Indications Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections; Meningococcal infections
  • Focus Pharmacodynamics
  • Sponsors Sanofi; sanofi pasteur
  • Most Recent Events

    • 22 Dec 2009 Actual patient numbers amended from 239 to 145 as reported by ClinicalTrials.gov.
    • 24 Sep 2008 Actual patient number (239) added as reported by ClinicalTrials.gov.
    • 24 Sep 2008 Actual end date (Dec 2007) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top